Related Experiment Video
Updated: Jun 4, 2026
08:28
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
New developments in hormone receptor-positive disease
1Medicine Department, Jules Bordet Institut, Brussels, Belgium. martine.piccart@bordet.be
The Oncologist
|February 1, 2011
Summary
Optimal management of hormone receptor-positive (HR+) breast cancer is challenging. Research is exploring tumor markers like Ki-67 and host markers to personalize endocrine therapy and differentiate between luminal A and B subtypes for better patient outcomes.
Area of Science:
- Oncology
- Endocrinology
- Genetics
Background:
- Hormone receptor-positive (HR+) breast cancer affects approximately 700,000 women annually.
- Endocrine therapy has improved outcomes but optimal management remains complex.
- Debates continue regarding adjuvant chemotherapy thresholds and optimal endocrine/chemotherapy regimens.
Purpose of the Study:
- To address outstanding challenges in the management of HR+ breast cancer.
- To explore the potential of tumor and host markers for personalized adjuvant endocrine therapy.
- To highlight the importance of distinguishing between luminal A and luminal B breast cancer subtypes.
Main Methods:
- Review of current research on HR+ breast cancer management.
- Investigation into the utility of markers such as Ki-67 and cytochrome P450 2D6.
- Analysis of emerging data differentiating luminal A and B breast cancer classifications.
Main Results:
- Hormone receptor-positive breast cancer management presents significant challenges.
- Tumor markers (e.g., Ki-67) and host markers (e.g., CYP2D6) show promise for tailored therapy.
- Luminal A and B breast cancers are increasingly recognized as distinct entities requiring tailored treatment approaches.
Conclusions:
- Personalized adjuvant endocrine therapy is a key area of research for HR+ breast cancer.
- Accurate differentiation of luminal subtypes is crucial for effective treatment strategies.
- Further research is needed to refine treatment decisions for HR+ breast cancer patients.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:08Intracellular Hormone Receptors
Lipid-soluble hormones diffuse across the plasma and nuclear membrane of target cells to bind to their specific intracellular receptors. These receptors act as transcription factors that regulate gene expression and protein synthesis in the target cell
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:22Target Cell Response to Hormones
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...